BioMarin Pharmaceutical Inc. saw its stock rise after the company announced a global patent settlement with Ascendis Pharma A/S that resolves disputes over Ascendis’s Yuviwel product.
Under the terms of the agreement, Ascendis will remit royalties to BioMarin equivalent to 20% of net U.S. sales of Yuviwel, with that obligation applied retroactively to the drug’s first commercial sale. For sales in the European Union, Brazil and South Korea, Ascendis will pay royalties equal to 18% of net sales through May 2030.
The settlement includes a license to BioMarin’s patents related to Yuviwel that covers both existing and potential future indications, specifically including achondroplasia and hypochondroplasia. The license also explicitly covers use of Yuviwel in combination with other medicines.
As part of the agreement, BioMarin will dismiss the pending Section 337 investigation before the U.S. International Trade Commission. The parties also agreed to resolve all claims tied to the asserted intellectual property, including litigation that had been pending in Brazil, Denmark, Germany, South Korea and in the Northern District of California.
The statement accompanying the settlement highlights BioMarin’s contributions in C-type natriuretic peptide technology and cites the company’s development of VOXZOGO (vosoritide). The deal is presented as both a recognition of those innovations and a framework intended to preserve access to therapies for children with achondroplasia worldwide.
The settlement lays out clear commercial terms for royalties and patent licensing, and it addresses multiple legal proceedings across jurisdictions. It also establishes a defined royalty horizon for several international markets through May 2030, while applying a specified U.S. royalty rate retroactively to the first commercial sale.
No additional terms, timelines beyond May 2030 for the specified regions, or financial amounts beyond the stated royalty percentages were disclosed in the announcement.